Nasus Pharma Ltd. (NSRX)
NYSEAMERICAN: NSRX · Real-Time Price · USD
4.000
+0.150 (3.90%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Company Description
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions.
It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose.
Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Nasus Pharma Ltd.
| Country | Israel |
| Founded | 2019 |
| IPO Date | Aug 14, 2025 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Brendan O'Grady |
Contact Details
Address: Yigal Alon 65 Tel Aviv-Yafo, 6744317 Israel | |
| Phone | 972 3 573 6632 |
| Website | nasuspharma.com |
Stock Details
| Ticker Symbol | NSRX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 2029039 |
| ISIN Number | IL0012181553 |
| Employer ID | 51-6022712 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Brendan P. O'Grady | Chief Executive Officer |
| Ehud Moshe Gilboa MBA | Co-Founder and Executive Chairman |
| Dr. Dalia Megiddo M.B.A., M.D., Ph.D. | Co-Founder, Director, Chief Medical Officer and Chief Development Officer? |
| Eyal Rubin M.B.A. | Chief Financial Officer and Executive Vice President |
| Yifat Bar | Vice President of Administration and Human Resources |
| Dr. Galia Temtsin Kryaz Ph.D. | Director of CMC and Product Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 20, 2026 | EFFECT | Notice of Effectiveness |
| Aug 19, 2026 | 6-K | Report of foreign issuer |
| Aug 19, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 17, 2026 | 6-K | Report of foreign issuer |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Jul 28, 2026 | 6-K | Report of foreign issuer |
| Jun 9, 2026 | 6-K | Report of foreign issuer |
| May 26, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 15, 2026 | SCHEDULE 13G | Filing |
| Apr 7, 2026 | SCHEDULE 13G | Filing |